Breaking: EPO revokes Broad’s CRISPR patent

In a dramatic reversal, a European Patent Office’s (EPO) board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

The new IP battleground in CRISPR-Cas

21 November 2023 Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.

Biotechnology

EPO’s new examination guidelines: what you need to know

6 April 2021 The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

Genetics

Zebrafish start-up secures CRISPR licence

18 February 2021 ERS Genomics has agreed to license CRISPR-Cas9 technology to a Barcelona-based start-up which uses a zebrafish-based research model.